Products
Platform
Research
Market
Learn
Compare Bajaj Finserv Healthcare Fund vs SBI Healthcare Opportunities Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹500 | ₹500 |
Expense Ratio | 2.38 | 1.93 |
NAV | ₹9.87 | ₹433.33 |
Fund Started | 06 Dec 2024 | 04 Jun 1999 |
Fund Size | ₹322.41 Cr | ₹3933.26 Cr |
Exit Load | 1% for redemption within 3 Months | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹500
₹500
Expense Ratio
2.38
1.93
NAV
₹9.87
₹433.33
Fund Started
06 Dec 2024
04 Jun 1999
Fund Size
₹322.41 Cr
₹3933.26 Cr
Exit Load
1% for redemption within 3 Months
Exit load of 0.50% if redeemed within 15 days
Returns
1 Year | - | 3.27% |
3 Year | - | 25.40% |
5 Year | - | 18.81% |
1 Year
-
3.27%
3 Year
-
25.40%
5 Year
-
18.81%
Holding Analysis
Equity | 95.64% | 96.36% |
Cash | 2.35% | 3.56% |
Equity
95.64%
96.36%
Cash
2.35%
3.56%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Divi's Laboratories Ltd. | 7.86% |
Sun Pharmaceutical Industries Ltd. | 7.21% |
Apollo Hospitals Enterprise Ltd. | 6.29% |
Cipla Ltd. | 5.61% |
Fortis Healthcare Ltd. | 3.51% |
Emcure Pharmaceuticals Ltd. | 3.45% |
Biocon Ltd. | 3.45% |
Dr. Reddy's Laboratories Ltd. | 3.44% |
Dr. Lal Pathlabs Ltd. | 3.34% |
Neuland Laboratories Ltd. | 3.25% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.94% |
Divi's Laboratories Ltd. | 6.36% |
Max Healthcare Institute Ltd. | 5.67% |
Cipla Ltd. | 4.59% |
Lupin Ltd. | 4.08% |
Lonza Group Ag | 4.06% |
Fortis Healthcare Ltd. | 3.70% |
Torrent Pharmaceuticals Ltd. | 3.66% |
Gland Pharma Ltd. | 3.54% |
Mankind Pharma Ltd. | 3.34% |
Fund Manager
Name | Sorbh Gupta | Tanmaya Desai |
Start Date | 28 Jul 2025 | 17 May 2024 |
Name
Sorbh Gupta
Tanmaya Desai
Start Date
28 Jul 2025
17 May 2024
About Fund
Description | The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 06 Dec 2024 | 04 Jun 1999 |
Description
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
06 Dec 2024
04 Jun 1999